Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-19 vaccine immunological studies in Finland
2021-004788-29Phase 4Active
- Sponsor
- Finnish Institute for Health and Welfare
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of tozinameran, elasomeran, ChAdOx1 nCoV-19, tozinameran + riltozinameran, tozinameran + famtozinameran and 1 more in coronavirus disease 2019 (COVID-19), sponsored by Finnish Institute for Health and Welfare. Started Sep 2021; status: active.
02
Drugs
tozinameranelasomeranChAdOx1 nCoV-19tozinameran + riltozinamerantozinameran + famtozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-004788-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004788-29.